Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 6/20 | 0.58 |
| ▸ | CYP4A11 | Q02928 | 6/20 | 0.58 |
| ▸ | ATR | Q13535 | 14/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30509486 | 1.00 | CYP4F2 (0.58) | CYP4F2CYP4A11ATR | |
| SCHEMBL19277442 | 0.85 | CYP4F2 (0.64) | CYP4F2CYP4A11ATR | |
| SCHEMBL18034742 | 0.85 | CYP4F2 (0.57) | CYP4F2CYP4A11ATR | |
| SCHEMBL9977842 | 0.84 | CYP4F2 (0.54) | CYP4F2CYP4A11ATR | |
| SCHEMBL24409265 | 0.82 | CYP4F2 (0.58) | CYP4F2CYP4A11ATR | |
| SCHEMBL19276681 | 0.81 | CYP4F2 (0.65) | CYP4F2CYP4A11ATR | |
| SCHEMBL13734367 | 0.80 | CYP4F2 (0.53) | CYP4F2CYP4A11ATR | |
| SCHEMBL25257638 | 0.80 | CYP4F2 (0.53) | CYP4F2CYP4A11ATR | |
| SCHEMBL19277056 | 0.80 | CYP4F2 (0.68) | CYP4F2CYP4A11ATR | |
| SCHEMBL25325198 | 0.79 | CYP4F2 (0.42) | CYP4F2CYP4A11ATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339900-A1 | CASEIN KINASE 1 DELTA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-26 | — | — | US | disclosed |
| US-20230339900-A1 | CASEIN KINASE 1 DELTA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-26 | — | — | US | disclosed |
| US-20230339900-A1 | CASEIN KINASE 1 DELTA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-26 | — | — | US | disclosed |
| EP-4214199-A1 | CASEIN KINASE 1 DELTA MODULATORS | JANSSEN Pharmaceutica NV (BE) | 2023-07-26 | — | — | EP | disclosed |
| CN-116490503-A | Casein kinase 1 delta modulators | 詹森药业有限公司 | 2023-07-25 | — | — | CN | disclosed |
| US-11198690-B2 | Method for producing (2S)-2-[(1H-pyrazol-1-yl)methyl]-1,3-oxazinane derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2021-12-14 | — | — | US | disclosed |
| US-20210147400-A1 | METHOD FOR PRODUCING (2S)-2-[(1H-PYRAZOL-1-YL)METHYL]-1,3-OXAZINANE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2021-05-20 | — | — | US | disclosed |
| EP-3653623-A1 | METHOD FOR PRODUCING (2S)-2-[(1H-PYRAZOL-1-YL)METHYL]-1,3-OXAZINANE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2020-05-20 | — | — | EP | disclosed |
| WO-2019013244-A1 | METHOD FOR PRODUCING (2S)-2-[(1H-PYRAZOL-1-YL)METHYL]-1,3-OXAZINANE DERIVATIVE | 大正製薬株式会社 | 2019-01-17 | — | — | WO | disclosed |
| EP-2862860-B1 | 1,3-OXAZOLIDINE OR 1,3-OXAZINANE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | TAISHO PHARMACEUTICAL CO LTD (JP) | 2016-12-21 | — | — | EP | disclosed |
| US-20150166523-A1 | BRANCHED CHAIN ALKYL HETEROAROMATIC RING DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-06-18 | — | — | US | disclosed |
| US-20150166523-A1 | BRANCHED CHAIN ALKYL HETEROAROMATIC RING DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-06-18 | — | — | US | disclosed |
| EP-2862860-A1 | HETEROAROMATIC METHYL CYCLIC AMINE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2015-04-22 | — | — | EP | disclosed |
| EP-2862855-A1 | BRANCHED CHAIN ALKYL HETEROAROMATIC RING DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2015-04-22 | — | — | EP | disclosed |
| WO-2013187466-A1 | BRANCHED CHAIN ALKYL HETEROAROMATIC RING DERIVATIVE | 大正製薬株式会社 (JP) | 2013-12-19 | — | — | WO | disclosed |
| US-20130281465-A1 | PYRAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-24 | — | — | US | disclosed |
| US-20130281465-A1 | PYRAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-24 | — | — | US | disclosed |
| US-20130281465-A1 | PYRAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-24 | — | — | US | disclosed |
| EP-2653469-A1 | PYRAZOLE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012081692-A1 | PYRAZOLE DERIVATIVE | 大正製薬株式会社 (JP) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166523-A1 | BRANCHED CHAIN ALKYL HETEROAROMATIC RING DERIVATIVE | HCRTR2, HCRTR1, HTR2B | CYP4F2 974/4885CYP4A11 467/4885ATR 4245/4885 |
| US-20230339900-A1 | CASEIN KINASE 1 DELTA MODULATORS | CSNK1D, CSNK1A1, CSNK2A1 | CYP4F2 3905/4885CYP4A11 2649/4885ATR 2354/4885 |
| US-11198690-B2 | Method for producing (2S)-2-[(1H-pyrazol-1-yl)methyl]-1,3-oxazinane derivative | AGXT, GRHPR, HPD | CYP4F2 317/4885CYP4A11 277/4885ATR 2179/4885 |
| US-20130281465-A1 | PYRAZOLE DERIVATIVE | HCRTR1, HCRTR2, NPY4R | CYP4F2 2278/4885CYP4A11 1266/4885ATR 4513/4885 |
| US-20210147400-A1 | METHOD FOR PRODUCING (2S)-2-[(1H-PYRAZOL-1-YL)METHYL]-1,3-OXAZINANE DERIVATIVE | AGXT, GRHPR, HPD | CYP4F2 317/4885CYP4A11 277/4885ATR 2179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.